Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAWN NYSE:JWS NASDAQ:KALV NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$7.12-3.4%$6.89$5.64▼$16.76$729.32M-1.251.05 million shs671,274 shsJWSJaws Acquisition$13.55$9.95▼$17.43$198.38MN/A904,340 shs159,142 shsKALVKalVista Pharmaceuticals$14.01-5.4%$14.14$7.30▼$17.28$745.53M-0.1889,385 shs2.23 million shsVALNValneva$8.94-2.6%$8.35$3.62▼$12.25$768.19M1.79127,130 shs40,127 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals0.00%-5.70%+13.92%+6.75%-49.47%JWSJaws Acquisition0.00%0.00%0.00%0.00%0.00%KALVKalVista Pharmaceuticals0.00%-11.44%+8.19%+8.10%+30.69%VALNValneva0.00%+3.35%-14.61%+48.75%+27.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$7.12-3.4%$6.89$5.64▼$16.76$729.32M-1.251.05 million shs671,274 shsJWSJaws Acquisition$13.55$9.95▼$17.43$198.38MN/A904,340 shs159,142 shsKALVKalVista Pharmaceuticals$14.01-5.4%$14.14$7.30▼$17.28$745.53M-0.1889,385 shs2.23 million shsVALNValneva$8.94-2.6%$8.35$3.62▼$12.25$768.19M1.79127,130 shs40,127 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals0.00%-5.70%+13.92%+6.75%-49.47%JWSJaws Acquisition0.00%0.00%0.00%0.00%0.00%KALVKalVista Pharmaceuticals0.00%-11.44%+8.19%+8.10%+30.69%VALNValneva0.00%+3.35%-14.61%+48.75%+27.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAWNDay One Biopharmaceuticals 3.13Buy$25.29255.14% UpsideJWSJaws Acquisition 0.00N/AN/AN/AKALVKalVista Pharmaceuticals 3.11Buy$26.4388.64% UpsideVALNValneva 3.00Buy$15.0067.79% UpsideCurrent Analyst Ratings BreakdownLatest JWS, KALV, VALN, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$28.009/12/2025KALVKalVista PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$27.00 ➝ $28.009/8/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $13.008/25/2025VALNValnevaJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$14.008/25/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/19/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.008/18/2025DAWNDay One BiopharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/6/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $16.008/6/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $25.007/8/2025KALVKalVista PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$19.00 ➝ $27.007/8/2025KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $27.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAWNDay One Biopharmaceuticals$187.64M3.89N/AN/A$4.99 per share1.43JWSJaws AcquisitionN/AN/AN/AN/A$6.45 per shareN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/A$1.92 per shareN/AVALNValneva$196.33M3.91$0.10 per share93.95$2.41 per share3.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAWNDay One Biopharmaceuticals-$95.50M-$0.95N/AN/AN/A-50.63%-19.01%-16.99%10/29/2025 (Estimated)JWSJaws Acquisition-$28.88MN/A0.00N/AN/AN/A-940.21%-6.80%N/AKALVKalVista Pharmaceuticals-$183.44M-$3.94N/AN/AN/AN/A-162.69%-88.61%N/AVALNValneva-$13.25M-$0.98N/AN/AN/A-33.87%-34.78%-13.43%11/6/2025 (Estimated)Latest JWS, KALV, VALN, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/11/2025Q1 2026KALVKalVista Pharmaceuticals-$0.91-$1.12-$0.21-$1.12$1.97 million$1.43 million8/12/2025Q2 2025VALNValneva-$0.27-$0.16+$0.11-$0.16$46.28 million$54.84 million8/5/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35-$0.29+$0.06-$0.29$35.55 million$33.91 million7/10/2025Q4 2025KALVKalVista Pharmaceuticals-$0.83-$3.69-$2.86-$0.99$4.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AJWSJaws AcquisitionN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAWNDay One BiopharmaceuticalsN/A9.659.53JWSJaws AcquisitionN/A0.200.56KALVKalVista PharmaceuticalsN/A5.355.35VALNValneva0.662.271.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAWNDay One Biopharmaceuticals87.95%JWSJaws Acquisition72.87%KALVKalVista PharmaceuticalsN/AVALNValneva11.39%Insider OwnershipCompanyInsider OwnershipDAWNDay One Biopharmaceuticals6.20%JWSJaws AcquisitionN/AKALVKalVista Pharmaceuticals4.30%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAWNDay One Biopharmaceuticals60102.43 million96.08 millionOptionableJWSJaws AcquisitionN/A86.25 millionN/ANot OptionableKALVKalVista Pharmaceuticals10050.34 million48.18 millionOptionableVALNValneva70085.93 million73.12 millionNot OptionableJWS, KALV, VALN, and DAWN HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN5 hours ago | globenewswire.comVaccine producer pledges to raise 10,000 for West Lothian charity partnerSeptember 13 at 3:40 PM | msn.comScotland’s largest vaccine producer pledges £10,000 to West Lothian charitySeptember 13 at 3:40 PM | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNSeptember 13 at 1:45 PM | prnewswire.comValneva SE Sponsored ADR (NASDAQ:VALN) Sees Significant Drop in Short InterestSeptember 13 at 11:17 AM | marketbeat.comValneva Scotland makes strides toward £10K fundraising goal in support of charity partner Team JakSeptember 12 at 10:26 AM | msn.comVALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the FirmSeptember 11 at 5:16 PM | globenewswire.comValneva (NASDAQ:VALN) Stock Price Up 5.6% - Should You Buy?September 11 at 1:12 PM | marketbeat.comLevi & Korsinsky Launches Fraud Investigation on Behalf of Valneva SE (VALN) ShareholdersSeptember 10, 2025 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNSeptember 10, 2025 | globenewswire.comValneva (NASDAQ:VALN) Price Target Lowered to $13.00 at GuggenheimSeptember 10, 2025 | marketbeat.comValneva (NASDAQ:VALN) Price Target Cut to $13.00 by Analysts at GuggenheimSeptember 10, 2025 | americanbankingnews.comA Lyme Disease Vaccine’s Final Test Results Could Appear By Yearend.September 9, 2025 | msn.comValneva price target lowered to $13 from $14 at GuggenheimSeptember 9, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNSeptember 8, 2025 | prnewswire.comShort Interest in Valneva SE Sponsored ADR (NASDAQ:VALN) Expands By 64.6%September 8, 2025 | marketbeat.comValneva (NASDAQ:VALN) Rating Increased to Hold at Wall Street ZenSeptember 8, 2025 | marketbeat.comValneva (NASDAQ:VALN) Raised to Hold at Wall Street ZenSeptember 8, 2025 | americanbankingnews.comValneva (NASDAQ:VALN) Trading Up 5% - Here's WhySeptember 5, 2025 | marketbeat.comVALNEVA Declaration of shares and voting rights: August 31, 2025September 5, 2025 | finance.yahoo.comVALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the FirmSeptember 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJWS, KALV, VALN, and DAWN Company DescriptionsDay One Biopharmaceuticals NASDAQ:DAWN$7.12 -0.25 (-3.39%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.12 0.00 (-0.07%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Jaws Acquisition NYSE:JWSJaws Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more operating businesses or entities. The company was incorporated in 2019 and is based in Miami Beach, Florida. Jaws Acquisition Corp. is a subsidiary of Jaws Sponsor LLC.KalVista Pharmaceuticals NASDAQ:KALV$14.01 -0.80 (-5.40%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$13.94 -0.06 (-0.46%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Valneva NASDAQ:VALN$8.94 -0.24 (-2.61%) As of 09/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
